0000950170-24-005557.txt : 20240118
0000950170-24-005557.hdr.sgml : 20240118
20240118194715
ACCESSION NUMBER: 0000950170-24-005557
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240116
FILED AS OF DATE: 20240118
DATE AS OF CHANGE: 20240118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mates Sharon
CENTRAL INDEX KEY: 0001585699
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36274
FILM NUMBER: 24543415
MAIL ADDRESS:
STREET 1: C/O INTRA-CELLULAR THERAPIES, INC.
STREET 2: 3960 BROADWAY
CITY: NEW YORK
STATE: NY
ZIP: 10032
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc.
CENTRAL INDEX KEY: 0001567514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364742850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: Oneida Resources Corp.
DATE OF NAME CHANGE: 20130122
4
1
ownership.xml
4
X0508
4
2024-01-16
0001567514
Intra-Cellular Therapies, Inc.
ITCI
0001585699
Mates Sharon
C/O INTRA-CELLULAR THERAPIES, INC.
430 EAST 29TH STREET
NEW YORK
NY
10016
true
true
false
false
Chairman, President & CEO
true
Common Stock
2024-01-16
4
M
false
75361
16.86
A
1125670
D
Common Stock
2024-01-16
4
S
false
3500
66.38
D
1122170
D
Common Stock
2024-01-16
4
S
false
65979
67.25
D
1056191
D
Common Stock
2024-01-16
4
S
false
5882
67.76
D
1050309
D
Common Stock
2024-01-17
4
M
false
48084
16.86
A
1098393
D
Common Stock
2024-01-17
4
S
false
30633
66.00
D
1067760
D
Common Stock
2024-01-17
4
S
false
17451
66.66
D
1050309
D
Common Stock
2024-01-18
4
M
false
67917
16.86
A
1118226
D
Common Stock
2024-01-18
4
S
false
67597
65.19
D
1050629
D
Common Stock
2024-01-18
4
S
false
320
66.25
D
1050309
D
Stock Option (right to buy)
16.86
2024-01-16
4
M
false
75361
0
D
2024-06-30
Common Stock
75361
124639
D
Stock Option (right to buy)
16.86
2024-01-17
4
M
false
48084
0
D
2024-06-30
Common Stock
48084
76555
D
Stock Option (right to buy)
16.86
2024-01-18
4
M
false
67917
0
D
2024-06-30
Common Stock
67917
8638
D
This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 14, 2023 and amended on June 9, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.685 to $66.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.69 to $67.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.69 to $67.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.36 to $66.3572, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.36 to $67.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.84 to $65.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.0143 to $66.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
This option was granted on June 30, 2014 with an exercise price of $16.86 per share and will expire on June 30, 2024. All shares underlying this option have vested.
/s/ Lawrence J. Hineline, Attorney-in-fact
2024-01-18